Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The main aim of the study is to investigate whether intranasal oxytocin (24IU) influences reward sensitivity and performance monitoring during reinforcement learning.
A double-blind, within-subject, placebo-controlled pharmacological EEG design will be employed. A total of 35 healthy male subjects will be recruited which will receive either intranasal placebo or oxytocin (24IU) on two separate study days (order counter-balanced, washout period at least 2 weeks). 45 minutes after treatment subjects will undergo a probabilistic feedback reinforcement learning paradigm with concurrent EEG acquisition. During the paradigm subjects will learn the reward probabilities of two different visual stimuli from probabilistic feedback provided by social stimuli (positive, negative emoticon). The paradigm includes an initial acquisition phase and a subsequent test phase.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Oxytocin then placebo | Experimental | Participants first receive oxytocin (24 IU). After a washout period of 2 weeks, they receive placebo. |
|
| Placebo then oxytocin | Experimental | Participants first receive placebo. After a washout period of 2 weeks, they receive oxytocin (24 IU). |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| intranasal oxytocin | Drug | 24 IU of oxytocin nasal spray will be applied to each subject. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Neural index: Event-related potential: Feedback Related Negativity (FRN) during acquisition phase | Feedback Related Negativity (FRN): a negative ERP component evoked by negative feedback relative to positive feedback during the acquisition phase will be compared between the oxytocin and placebo treatment conditions. | 45-105 minutes after treatment administration |
| Neural index: Event-related potential: Error Related Negativity (ERN) during the test phase | Error Related Negativity (ERN): a negative ERP component evoked by incorrect responses relative to correct responses during the test phase will be compared between the oxytocin and placebo treatment conditions. | 45-105 minutes after treatment administration |
| Measure | Description | Time Frame |
|---|---|---|
| Behavioral index: Response accuracy to superior stimuli during the acquisition phase | Correct responses are defined as choices of the stimulus associated with higher probability positive feedback during the acquisition phase. Effects of treatment will be analyzed by comparing the performance between the two treatment conditions. | 45-105 minutes after treatment administration |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Zhuang Qian, MD | Contact | 13086663679 | zq19910362@126.com | |
| Benjamin Becker, PhD | Contact | 86-28-61830988 | ben_becker@gmx.de |
| Name | Affiliation | Role |
|---|---|---|
| Keith Kendrick, PhD | University of Electronic Science and Technology of China(UESTC) | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University of Electronic Science and Technology of China(UESTC) | Recruiting | Chengdu | Sichuan | 611731 | China |
Not provided
| ID | Term |
|---|---|
| D007859 | Learning Disabilities |
| ID | Term |
|---|---|
| D003147 | Communication Disorders |
| D019954 | Neurobehavioral Manifestations |
| D009461 | Neurologic Manifestations |
| D009422 | Nervous System Diseases |
Not provided
Not provided
Randomized placebo-controlled double-blind within-subject design
Not provided
Not provided
Not provided
| intranasal placebo | Drug | an identical amount of placebo nasal spray will be applied to each subject. |
|
| Behavioral index: Response accuracy to stimuli associated with highest probability positive feedback during the test phase | Correct responses are defined as choices of the stimulus associated with highest probability positive feedback as learned in the acquisition phase. Effects of treatment will be analyzed by comparing the performance between the two treatment conditions. | 45-105 minutes after treatment administration |
| Response accuracy avoiding stimuli associated with highest probability negative feedback in the test phase. | Correct responses are defined as avoidance choices of stimuli associated with highest probability negative feedback as learned in the acquisition phase. Effects of treatment will be analyzed by comparing the performance between the two treatment conditions. | 45-105 minutes after treatment administration |
| Response accuracy in response to superior stimuli associated with relative higher probability positive feedback in the test phase. | Correct responses are defined as choices of the stimulus associated with higher probability positive feedback. Note that stimuli pairs in this measurement are all associated with positive feedback. Effects of treatment will be analyzed by comparing the performance between the two treatment conditions. | 45-105 minutes after treatment administration |
| Response accuracy avoiding stimuli associated with higher probability negative feedback in the test phase. | Correct responses are defined as avoidance choices of stimuli associated with higher probability negative feedback. Note that stimuli pairs in this measurement are all associated with negative feedback. Effects of treatment will be analyzed by comparing the performance between the two treatment conditions. | 45-105 minutes after treatment administration |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D065886 | Neurodevelopmental Disorders |
| D001523 | Mental Disorders |